GPX4 and leukemia: Collectively, these results demonstrate that circulating EVs from AML patients may trigger CD34+ AML cells toward an increase in both mitochondrial potential and GSH levels, reducing ROS levels and showing a leukemia-dependent mechanism partially reverted by GPX4 inhibition.